Advancing patient-led science through collaboration

The Rare As One Cycle 2 Impact Report highlights how patient communities are accelerating research and reshaping the rare disease landscape.

A large group photo of people standing together, smiling and waving outdoors among palm trees.
RAO Network Cycle 2 grantees pose with fellow attendees at the CZI Science in Society 2025 Meeting in Las Vegas, Nevada.

In 2019, we launched the Rare As One (RAO) Project — a program aiming to elevate patient communities as central stakeholders in research. Foundational to the program is the RAO Network, currently consisting of 94 patient-led rare disease organizations. Building on the success and impact of the first cycle of 30 grantees, the second cycle of the Network consisted of 20 patient-led rare disease organizations to accelerate research in their disease areas. The Rare As One Cycle 2 Impact Report: Advancing Patient-Led Science Through Community-Driven Research highlights the achievements and collective impact of these organizations.

Like Cycle 1, the RAO Network Cycle 2 has demonstrated the transformative power of patient-led research organizations in advancing scientific discovery and improving lives. Their achievements are blazing the trail for an emerging model of patient-driven research that is accelerating scientific progress and reshaping the rare disease landscape.

Cycle 2 grantees have:

  • Engaged more than 6,000 new researchers.
  • Launched 13 patient registries and 12 natural history studies.
  • Collaborated with 65 industry partners.
  • Supported more than 150 research projects.

These patient-led organizations have demonstrated that urgency, lived experience and scientific rigor are not only compatible — they are synergistic forces that accelerate breakthrough discoveries.

This report, developed in partnership with Cycle 2 of the RAO Network, provides a snapshot of the tremendous scientific momentum and progress these organizations have inspired, and highlights the impact that a network of similarly placed and determined patient-led organizations can have when provided with baseline funding, support and opportunities to collaborate with one another.

Explore the full report.

News

  • GEN: Virtual Cells Go Multiscale to Predict Complex Biology

    AI models inform therapeutics that can restore diseased cells to healthy states

  • Protein Modeling, Cell Imaging and Patient-Powered Science: Reflections on Biohub’s Start to the Year

    Co-founder Priscilla Chan shares reflections following Aspen Ideas: Health on the models, tools, and people driving Biohub's progress this year.

  • Surprising drug targets for psoriasis emerge from comprehensive CRISPR study of human skin cells

    Analysis of results by AI ‘novelty filter’ led researchers to formulate topical gels that, in mice, were as effective as widely used injected therapy.